Endogenous opioid systems: Current concepts and clinical correlations

Neurology

Volumn 79, Issue 8, 2012, Pages 807-814

  Benarroch, Eduardo E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; BETA ENDORPHIN; DOPAMINE; DYNORPHIN; ENDOMORPHIN 1; ENKEPHALIN; G PROTEIN COUPLED RECEPTOR; INWARDLY RECTIFYING POTASSIUM CHANNEL; KAPPA OPIATE RECEPTOR; LEVODOPA; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; NOCICEPTIN; NOCICEPTIN RECEPTOR; OPIATE RECEPTOR; PREPROENKEPHALIN; REMIFENTANIL; RETINA S ANTIGEN; SEROTONIN RECEPTOR; VOLTAGE GATED CALCIUM CHANNEL;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; BASAL GANGLION; BRAIN CORTEX; CORRELATION ANALYSIS; DESENSITIZATION; DOPAMINE RELEASE; DOWN REGULATION; DRUG DEPENDENCE; DYSKINESIA; FUSIFORM GYRUS; GABAERGIC TRANSMISSION; HUMAN; HYPERALGESIA; HYPOTHALAMUS; INHIBITION KINETICS; INTERNEURON; MIDDLE CEREBRAL ARTERY; NERVE CELL NETWORK; NERVE DEGENERATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NOCICEPTION; NONHUMAN; NUCLEUS ACCUMBENS; PAIN; PARKINSON DISEASE; POSTSYNAPTIC INHIBITION; PREFRONTAL CORTEX; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEIZURE; SIGNAL TRANSDUCTION; SPINAL ANESTHESIA; SPINAL GANGLION; TEMPORAL GYRUS; UPREGULATION; VENTRAL TEGMENTUM;

EID: 84866113435     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182662098     Document Type: Article

References (56)

1. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physic 2008;11:S133-S153.
2. Bodnar RJ. Endogenous opiates and behavior: 2010. Peptides 2010;32:2522-2552.
3. Pradhan AA, Befort K, Nozaki C, Gaveriaux-Ruff C, Kieffer BL. The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci 2011;32:581-590.
4. Nandhu MS, Naijil G, Smijin S, Jayanarayanan S, Paulose CS. Opioid system functional regulation in neurological disease management. J Neurosci Res 2010;88:3215-3221.
5. Maldonado R. [The endogenous opioid system and drug addiction.] Ann Pharmaceut Franc 2010;68:3-11.
6. Vanderah TW. Delta and kappa opioid receptors as suitable drug targets for pain. Clin J Pain 2010;26(suppl 10):S10-S15.
7. Trigo JM, Martin-Garcia E, Berrendero F, Robledo P, Maldonado R. The endogenous opioid system: a common substrate in drug addiction. Drug Alcohol Depend 2010;108:183-194.
8. Le Merrer J, Becker JA, Befort K, Kieffer BL. Reward processing by the opioid system in the brain. Physiol Rev 2009;89:1379-1412.
9. Dietis N, Rowbotham DJ, Lambert DG. Opioid receptor subtypes: fact or artifact? Br J Anaesth 2011;107:8-18.
10. Rachinger-Adam B, Conzen P, Azad SC. Pharmacology of peripheral opioid receptors. Curr Opin Anaesthesiol 2011;24:408-413.
11. Sauriyal DS, Jaggi AS, Singh N. Extending pharmacological spectrum of opioids beyond analgesia: multifunctional aspects in different pathophysiological states. Neuropeptides 2011;45:175-188.
12. Mika J, Obara I, Przewlocka B. The role of nociceptin and dynorphin in chronic pain: implications of neuro-glial interaction. Neuropeptides 2011;45:247-261.
13. Samadi P, Bedard PJ, Rouillard C. Opioids and motor complications in Parkinson's disease. Trends Pharmacol Sci 2006;27:512-517.
14. Blomeley CP, Bracci E. Opioidergic interactions between striatal projection neurons. J Neurosci 2011;31:13346-13356.
15. Marvizon JC, Chen W, Murphy N. Enkephalins, dynorphins, and beta-endorphin in the rat dorsal horn: an immunofluorescence colocalization study. J Comp Neurol 2009;517:51-68.
16. Cahill CM, Holdridge SV, Morinville A. Trafficking of delta-opioid receptors and other G-protein-coupled receptors: implications for pain and analgesia. Trends Pharmacol Sci 2007;28:23-31.
17. van Rijn RM, Whistler JL, Waldhoer M. Opioid-receptorheteromer-specific trafficking and pharmacology. Curr Opin Pharmacol 2010;10:73-79.
18. Chakrabarti S, Liu NJ, Gintzler AR. Formation of mu-/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia. Proc Natl Acad Sci USA 2010;107:20115-20119.
19. Stone LS, Wilcox GL. Alpha-2-adrenergic and opioid receptor additivity in rat locus coeruleus neurons. Neurosci Lett 2004;361:265-268.
20. Overland AC, Kitto KF, Chabot-Dore AJ, et al. Protein kinase C mediates the synergistic interaction between agonists acting at alpha2-adrenergic and delta-opioid receptors in spinal cord. J Neurosci 2009;29:13264-13273.
21. Lopez-Moreno JA, Lopez-Jimenez A, Gorriti MA, de Fonseca FR. Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors. Curr Drug Targets 2010;11:406-428.
22. Parolaro D, Rubino T, Vigano D, Massi P, Guidali C, Realini N. Cellular mechanisms underlying the interaction between cannabinoid and opioid system. Curr Drug Targets 2010;11:393-405.
23. Frolich N, Dees C, Paetz C, et al. Distinct pharmacological properties of morphine metabolites at G (i)-protein and beta-arrestin signaling pathways activated by the human mu-opioid receptor. Biochem Pharmacol 2011;81:1248-1254.
24. Pradhan AA, Walwyn W, Nozaki C, et al. Ligand-directed trafficking of the delta-opioid receptor in vivo: two paths toward analgesic tolerance. J Neurosci 2010;30:16459-16468.
25. Hosobuchi Y, Adams JE, Linchitz R. Pain relief by electrical stimulation of the central gray matter in humans and its reversal by naloxone. Science 1977;197:183-186.
26. Butler RK, Finn DP. Stress-induced analgesia. Prog Neurobiol 2009;88:184-202.
27. Wager TD, Scott DJ, Zubieta JK. Placebo effects on human mu-opioid activity during pain. Proc Natl Acad Sci USA 2007;104:11056-11061.
28. Carlino E, Pollo A, Benedetti F. Placebo analgesia and beyond: a melting pot of concepts and ideas for neuroscience. Curr Opin Anaesthesiol 2011;24:540-544.
29. Zhao ZQ. Neural mechanism underlying acupuncture analgesia. Prog Neurobiol 2008;85:355-375.
30. Zheng W. Activation of mu opioid receptor inhibits the excitatory glutamatergic transmission in the anterior cingulate cortex of the rats with peripheral inflammation. Eur J Pharmacol 2010;628:91-95.
31. Fields H. State-dependent opioid control of pain. Nat Rev 2004;5:565-575.
32. Upadhyay J, Anderson J, Baumgartner R, et al. Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine. NeuroImage 2012;59:3762-3773.
33. Eippert F, Bingel U, Schoell ED, et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 2009;63:533-543.
34. de Andrade DC, Mhalla A, Adam F, Texeira MJ, Bouhassira D. Neuropharmacological basis of rTMS-induced analgesia: the role of endogenous opioids. Pain 2011;152:320-326.
35. Shimoyama M, Toyama S, Tagaito Y, Shimoyama N. Endogenous endomorphin-2 contributes to spinal k-opioid antinociception. Pharmacology 2012;89:145-148.
36. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011;14:145-161.
37. Heinl C, Drdla-Schutting R, Xanthos DN, Sandkuhler J. Distinct mechanisms underlying pronociceptive effects of opioids. J Neurosci 2011;31:16748-16756.
38. Solbrig MV, Adrian R, Baratta J, Lauterborn JC, Koob GF. Kappa opioid control of seizures produced by a virus in an animal model. Brain 2006;129:642-654.
39. Loacker S, Sayyah M, Wittmann W, Herzog H, Schwarzer C. Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors. Brain 2007;130:1017-1028.
40. Hammers A, Asselin MC, Hinz R, et al. Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain 2007;130:1009-1016.
41. Cuellar-Herrera M, Velasco AL, Velasco F, et al. Mu opioid receptor mRNA expression, binding, and functional coupling to G-proteins in human epileptic hippocampus. Hippocampus 2012;22:122-127.
42. Rocha L, Orozco-Suarez S, Alonso-Vanegas M, et al. Temporal lobe epilepsy causes selective changes in mu opioid and nociceptin receptor binding and functional coupling to G-proteins in human temporal neocortex. Neurobiol Dis 2009;35:466-473.
43. Panuccio G, Curia G, Colosimo A, Cruccu G, Avoli M. Epileptiform synchronization in the cingulate cortex. Epilepsia 2009;50:521-536.
44. Zhu M, Li MW, Tian XS, Ou XM, Zhu CQ, Guo JC. Neuroprotective role of delta-opioid receptors against mitochondrial respiratory chain injury. Brain Res 2009;1252:183-191.
45. Zhu M, Li M, Yang F, et al. Mitochondrial ERK plays a key role in delta-opioid receptor neuroprotection against acute mitochondrial dysfunction. Neurochem Int 2011;59:739-748.
46. Su DS, Wang ZH, Zheng YJ, Zhao YH, Wang XR. Dosedependent neuroprotection of delta opioid peptide [D-Ala2, D-Leu5] enkephalin in neuronal death and retarded behavior induced by forebrain ischemia in rats. Neurosci Lett 2007;423:113-117.
47. Gao CJ, Niu L, Ren PC, et al. Hypoxic preconditioning attenuates global cerebral ischemic injury following asphyxial cardiac arrest through regulation of delta opioid receptor system. Neuroscience 2012;202:352-362.
48. Yang L, Wang H, Shah K, Karamyan VT, Abbruscato TJ. Opioid receptor agonists reduce brain edema in stroke. Brain Res 2011;1383:307-316.
49. Cui J, Wang Y, Dong Q, et al. Morphine protects against intracellular amyloid toxicity by inducing estradiol release and upregulation of Hsp70. J Neurosci 2011;31:16227-16240.
50. Hu S, Sheng WS, Rock RB. Immunomodulatory properties of kappa opioids and synthetic cannabinoids in HIV-1 neuropathogenesis. J Neuroimmune Pharmacol 2011;6:528-539.
51. Avdoshina V, Biggio F, Palchik G, Campbell LA, Mocchetti I. Morphine induces the release of CCL5 from astrocytes: potential neuroprotective mechanism against the HIV protein gp120. Glia 2010;58:1630-1639.
52. Mendez M, Barbosa-Luna IG, Perez-Luna JM, Cupo A, Oikawa J. Effects of acute ethanol administration on methionine-enkephalin expression and release in regions of the rat brain. Neuropeptides 2010;44:413-420.
53. Mendez M, Morales-Mulia M. Role of mu and delta opioid receptors in alcohol drinking behaviour. Curr Drug Abuse Rev 2008;1:239-252.
54. Spreckelmeyer KN, Paulzen M, Raptis M, et al. Opiateinduced dopamine release is modulated by severity of alcohol dependence: an [(18) F]fallypride positron emission tomography study. Biol Psychiatry 2011;70:770-776.
55. Mitchell JM, O'Neil JP, Janabi M, Marks SM, Jagust WJ, Fields HL. Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. Sci Transl Med 2012;4:116.
56. Hillemacher T, Heberlein A, Muschler MA, Bleich S, Frieling H. Opioid modulators for alcohol dependence. Exp Opinion Invest Drugs 2011;20:1073-1086.